<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="been statistically verified as a stroke risk factor but high" exact="ergotamine" post="consumption is possibly associated with an increased risk of"/>
 <result pre="regimen after PFO closure, and found that the combination of" exact="clopidogrel" post="and aspirin resulted in fewer patients (12.2%) reported aura"/>
 <result pre="state-of the-art RCT of transcatheter ASD closure, the use of" exact="clopidogrel" post="and aspirin, compared with aspirin alone, resulted in a"/>
 <result pre="double-blinded, randomized parallel-group controlled study, the effect of 25 mg intranasal" exact="ketamine" post="was compared to 2 mg intranasal midazolam as an active"/>
 <result pre="effect of 25 mg intranasal ketamine was compared to 2 mg intranasal" exact="midazolam" post="as an active control. In the 18 subjects with"/>
 <result pre="18 subjects with migraine with prolonged aura completing the study," exact="ketamine" post="reduced the severity but not duration of aura, while"/>
 <result pre="ketamine reduced the severity but not duration of aura, while" exact="midazolam" post="was ineffective [ 59]. The usefulness of ketamine for"/>
 <result pre="aura, while midazolam was ineffective [ 59]. The usefulness of" exact="ketamine" post="for aura-treatment in classical migraine aura remains to be"/>
 <result pre="with migraine with aura, out of whom 95 (46.8%) used" exact="acetylsalicylic acid" post="and reported a &quot;positive effect&quot; and a significant reduction"/>
 <result pre="a larger double-blind, placebo-controlled study. A small open-label trial of" exact="levetiracetam" post="included 16 patients with migraine with aura, and led"/>
 <result pre="[ 63]. Another potential way of targeting CSD is using" exact="amiloride" post="a blocker of epithelial sodium channels based upon the"/>
 <result pre="CSD in animal studies. In a small open-labelled pilot study," exact="amiloride" post="reduced aura and headache symptoms in 4 of 7"/>
 <result pre="Triptans Previous studies indicated that triptans, specifically sumatriptan, eletriptan, and" exact="zolmitriptan" post="[ 67– 69], were not effective in relieving migraine"/>
 <result pre="the placebo, neither statistically not clinically significant [ 67]. The" exact="eletriptan" post="study found no significant difference in the proportion of"/>
 <result pre="of patients not developing moderate-to-severe headache within 6 h post-dose of" exact="eletriptan" post="(61%, 22/36 patients) versus placebo (46%, 19/41); P = 0.25)."/>
 <result pre="therapeutic gain of 15% and a NNT of 6.7 for" exact="eletriptan" post="taken during aura. In a small, four-way crossover open-label"/>
 <result pre="aura. In a small, four-way crossover open-label study, treatment with" exact="sumatriptan" post="100 mg during aura prevented the development of the headache"/>
 <result pre="phase [ 70– 72]. In the seminal RCT of subcutaneous" exact="sumatriptan" post="[ 73] the primary endpoint was pain relief at"/>
 <result pre="with their migraine and those without aura responded similarly to" exact="sumatriptan" post="with a therapeutic gain of 43% for attacks with"/>
 <result pre="consistent with our report of numerically better treatment effect of" exact="sumatriptan" post="in attacks without aura (see below). In another of"/>
 <result pre="aura (see below). In another of the first RCTs of" exact="sumatriptan" post="(200 mg vs placebo), patients were asked to treat three"/>
 <result pre="to a higher placebo respons [ 74]. Systematic reviews of" exact="sumatriptan" post="trials found insufficient data to carry out any sensitivity"/>
 <result pre="individual migraine attacks with aura vs. without aura, and for" exact="sumatriptan" post="we also compared patients with a diagnosis of MA"/>
 <result pre="[ 79]. The pooled pain free rates 2 h post-dose for" exact="sumatriptan" post="100 mg were significantly higher in patients treating attacks without"/>
 <result pre="analysis of pooled data from multiple randomized trials indicates that" exact="sumatriptan" post="is less effective as acute therapy for migraine attacks"/>
 <result pre="a translational model for migraine prophylaxis [ 90]. In rats" exact="lamotrigine" post="and valproate also suppressed CSD [ 91]. If CSD"/>
 <result pre="model for migraine prophylaxis [ 90]. In rats lamotrigine and" exact="valproate" post="also suppressed CSD [ 91]. If CSD plays a"/>
 <result pre="randomized, double-blind, placebo-controlled trial in patients with migraine without aura," exact="memantine" post="led to an significant reduction in headache [ 94]."/>
 <result pre="headache [ 94]. Based on the proposed mode of action," exact="memantine" post="should also work in migraine with aura. In a"/>
 <result pre="with the release of glutamate into the extracellular space and" exact="lamotrigine" post="has been shown to suppress CSD in the rat"/>
 <result pre="a positive pilot-study [ 97], a larger open-label study of" exact="lamotrigine" post="examined the prevention of migraine aura and reported that"/>
 <result pre="of migraine headaches [ 98]. Another open-label study examined whether" exact="lamotrigine" post="could cause a &amp;gt; 50% reduction in the mean frequency of"/>
 <result pre="responders). Auras reappeared in 9 out of 13 patients when" exact="lamotrigine" post="was stopped, but could be controlled as soon as"/>
 <result pre="The authors also state that the reduction in auras during" exact="topiramate" post="treatment tended to be somewhat more pronounced than the"/>
 <result pre="103]. Another study randomized 213 subjects from 27 centers to" exact="topiramate" post="or placebo [ 104]. Seventy-five (35.5%) subjects in the"/>
 <result pre="change in mean monthly migraine frequency was not different between" exact="topiramate" post="and placebo. In a subgroup analysis, a significant difference"/>
 <result pre="analysis, a significant difference was found in MA patients between" exact="topiramate" post="( n = 46) and placebo ( n = 29). In"/>
 <result pre="&quot;visual symptoms&quot; was not a predictor for treatment response to" exact="topiramate" post="[ 105]. Transcranial magnetic simulation Transcranial magnetic simulation (TMS)"/>
 <result pre="of ischemic complications related to the intensity of triptan and" exact="ergotamine" post="use Neurology 2006 67 7 1128 1134 10.1212/01.wnl.0000240128.76399.fa 17030745"/>
 <result pre="patients with familial hemiplegic migraine can be stopped by intranasal" exact="ketamine" post="Neurology 2000 55 1 139 141 10.1212/WNL.55.1.139 10891926 59."/>
 <result pre="Afridi SK et al. A randomized controlled trial of intranasal" exact="ketamine" post="in migraine with prolonged aura Neurology 2013 80 7"/>
 <result pre="1 S161 S163 10.1007/s10072-013-1413-x 67. Bates, D., et al., Subcutaneous" exact="sumatriptan" post="during the migraine aura . Sumatriptan Aura Study Group"/>
 <result pre="10.1159/000119101 8791030 69. Olesen J et al. No effect of" exact="eletriptan" post="administration during the aura phase of migraine European journal"/>
 <result pre="10.1111/j.1468-1331.2004.00914.x 70. Aurora SK et al. Revisiting the efficacy of" exact="sumatriptan" post="therapy during the aura phase of migraine Headache 2009"/>
 <result pre="79. Hansen JM Goadsby PJ Charles A Reduced efficacy of" exact="sumatriptan" post="in migraine with aura vs without aura Neurology 2015"/>
 <result pre="al. Cessation versus continuation of 6-month migraine preventive therapy with" exact="topiramate" post="(PROMPT): a randomised, double-blind, placebo-controlled trial Lancet Neurol 2007"/>
 <result pre="and without aura and their response to preventive therapy with" exact="topiramate" post="Cephalalgia 2009 30 5 543 551 10.1111/j.1468-2982.2009.01999.x 104. Silberstein"/>
 <result pre="10.1111/j.1468-2982.2009.01999.x 104. Silberstein SD et al. Efficacy and tolerability of" exact="topiramate" post="200 mg/d in the prevention of migraine with/without aura"/>
</results>
